A Phase 2 interventional study of D-Cycloserine and Intermittent Theta Burst Stimulation in Major Depressive Disorder, sponsored by The Alfred. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by The Alfred · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cycloserine in Depressive Disorder, Major — 2 open to participants now, 3 under way, none of them phase 3. Cycloserine · Depressive Disorder, Major.
Among the 10 studies testing cycloserine in Depressive Disorder, Major, this one is the 2nd largest by planned enrollment, is the only one that started in 2023, is one of 5 in phase 2, and was the 7th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 10 studies testing cycloserine in Depressive Disorder, Major are open now, in 1 country. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18+ · Healthy volunteers
Mclean Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Cycloserine: first FDA approval 1964 (SEROMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6
First in 2007; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 43 across the 10 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 7 most frequent:
The Alfred is the lead sponsor of 47 studies on the registry; 4 are open to participants now.
The Alfred has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cycloserine in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate if the drug D-Cycloserine (DCS) improves the antidepressant effects of Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation therapy, in patients with Major Depressive Disorder (MDD). The main questions it aims to answer are:
Major Depressive Disorder (MDD) is a common and debilitating condition with high rates of treatment resistance. Repetitive transcranial magnetic stimulation (rTMS) is an established treatment for treatment-resistant depression with few adverse effects. Intermittent Theta Burst Stimulation (iTBS) is a time-efficient form of rTMS with evidence base in the treatment of treatment-resistant depression (TRD). The most commonly supported understanding of iTBS's mechanism of action appear to be its strengthening of connections between networks of neurons, which is modulated by the N-methyl-D-aspartate (NMDA) receptor. D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. This study protocol proposes the conduct of a prospective multi-site, parallel-arm design, randomized, double-blinded, placebo-controlled clinical trial to investigate DCS augmentation of iTBS in MDD. We will investigate if adjuvant DCS 50mg or 100mg/day might have superior iTBS antidepressant augmentation effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 50mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
Drug: D-Cycloserine · Device: Intermittent Theta Burst Stimulation
Active iTBS (600 pulses), 5 days/week x 4 weeks + active DCS 100mg/day x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
Drug: D-Cycloserine · Device: Intermittent Theta Burst Stimulation
Active iTBS (600 pulses), 5 days/week x 4 weeks + placebo x 2 weeks, taken 2-hours prior to scheduled iTBS treatment.
Device: Intermittent Theta Burst Stimulation
D-cycloserine (DCS) is a partial NMDA receptor agonist that has demonstrable impact on rTMS and TBS's neuromodulatory effects. Participants will be asked to orally ingest one capsule 2-hours prior to their scheduled iTBS treatment time.
Intermittent Theta Burst Stimulation (iTBS) will be administered with a magnetic stimulator using a figure-of-8 coil or equivalent FDA-approved device. Initial treatment coil localisation and individual calibration of stimulation intensity will be conducted by TMS-trained investigators/staff using standard approaches.67,68 Stimulation intensity will be at 90% of the individual's calibrated resting motor threshold. iTBS treatment session delivers 600 pulses and is approximately 3½ minutes in duration. The total pulse number applied over a course of 20 treatments will be 12,000. This regimen is analogous with the iTBS protocol approved by the US FDA to treat TRD.
Rate of treatment response as per Montgomery Åsberg Depression Rating Scale (MADRS)
Clinical treatment response defined as \>/= 50% reduction in MADRS scores from baseline to primary study endpoint. Clinician-administered depression rating scale. The overall score ranges from 0 - 60. Cutoff points are 0-6 = normal, 7-9 = mild depression, 20-34 = moderate depression, \>34 = severe depression.
Time frame: Determined at Week 4 (primary study endpoint)
Change in Montgomery Åsberg Depression Rating Scale (MADRS)
Clinician-administered depression rating scale. The overall score ranges from 0 - 60. Cutoff points are 0-6 = normal, 7-9 = mild depression, 20-34 = moderate depression, \>34 = severe depression.
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Change in Clinical Global Impression (CGI)
Clinician assessment of overall illness severity and global functioning. The CGI-Severity scale is clinician rated from 1-7 representing 'Not at all ill' to 'Severely ill'. The CGI-Improvement scale is also rated 1-7, representing the range between 'Very much improved' and 'Very much worse'.
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Change in Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
Self-reported symptom rating scale for depression severity. Severity of depression can be judged based on the total score. 1-5 = No depression 6-10 = Mild depression 11-15 = Moderate depression 16-20 = Severe depression 21-27 = Very severe depression.
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Beck's Anxiety Inventory (BAI)
Self-reported symptom rating scale for anxiety severity. The score range is 0-63. A total score of 0-7 is considered minimal range, 8-15 is mild, 16-25 is moderate, and 26-63 is severe.
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
International Trauma Questionnaire (ITQ)
Self-reported symptom rating of trauma-related symptoms and their severity. All ITQ items are answered on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely).
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Beck's Scale for Suicide Ideation (BSS)
Self-reported symptom rating scale for suicidal ideation. Scores range from 0 to 38, a higher score indicating a higher level of suicide ideation.
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Change in World Health Organization Quality of Life (WHOQOL-BREF)
Self-reported rating scale of quality of life. Domains scores are calculated to range from 0-20 and scaled in a positive direction (ie. higher scores denote higher quality of life).
Time frame: Administered at baseline and at the ends of weeks 1, 2, 3 and 4 of treatment.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for May 2026, 37 months after the start.
Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 37 months is close to that.
Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cycloserine
The Alfred